Howard Sofen

15PUBLICATIONS
59CO-AUTHORS
Epidemiological methodsPharmacogenomicsPharmaceutical delivery technologiesAvionicsPhotography, video and lens-based practice
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

|Dec 05, 2025
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.

April W Armstrong, Richard B Warren, Howard Sofen

|Mar 06, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.

April W Armstrong, Mark Lebwohl, Richard B Warren

|Feb 07, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.

Joseph F Merola, Laura K Ferris, Jeffrey M Sobell

|Jan 08, 2025
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.

Eric L Simpson, Adelaide A Hebert, John Browning

|Dec 03, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.

John E Harris, Amit G Pandya, Mark Lebwohl

Pageof 3

Frequent Collaborators

5 joint publications

Richard B Warren

3 joint publications

Bruce Strober

3 joint publications

Kim Papp

3 joint publications

Diamant Thaçi